Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine

Gabriele Bianchi Porro, Fabio Pace, Alberto Peracchia, Luigi Bonavina, Sergio Vigneri, Anna Scialabba, Massimo Franceschi

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.

Original languageEnglish
Pages (from-to)192-198
Number of pages7
JournalJournal of Clinical Gastroenterology
Volume15
Issue number3
Publication statusPublished - 1992

Fingerprint

Peptic Esophagitis
Ranitidine
Omeprazole
Therapeutics
Esophageal pH Monitoring
Heartburn
Gastroesophageal Reflux
Multivariate Analysis

Keywords

  • Drug resistance
  • Histamine H2-receptor blockers
  • Omeprazole
  • Ranitidine
  • Reflux esophagitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Porro, G. B., Pace, F., Peracchia, A., Bonavina, L., Vigneri, S., Scialabba, A., & Franceschi, M. (1992). Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. Journal of Clinical Gastroenterology, 15(3), 192-198.

Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. / Porro, Gabriele Bianchi; Pace, Fabio; Peracchia, Alberto; Bonavina, Luigi; Vigneri, Sergio; Scialabba, Anna; Franceschi, Massimo.

In: Journal of Clinical Gastroenterology, Vol. 15, No. 3, 1992, p. 192-198.

Research output: Contribution to journalArticle

Porro, GB, Pace, F, Peracchia, A, Bonavina, L, Vigneri, S, Scialabba, A & Franceschi, M 1992, 'Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine', Journal of Clinical Gastroenterology, vol. 15, no. 3, pp. 192-198.
Porro, Gabriele Bianchi ; Pace, Fabio ; Peracchia, Alberto ; Bonavina, Luigi ; Vigneri, Sergio ; Scialabba, Anna ; Franceschi, Massimo. / Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. In: Journal of Clinical Gastroenterology. 1992 ; Vol. 15, No. 3. pp. 192-198.
@article{343511b800c84c69bd0881cc84436888,
title = "Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine",
abstract = "Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50{\%} of patients on omeprazole 20 mg daily, compared with 20.7{\%} on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3{\%} versus 34.5{\%} (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6{\%} of patients on omeprazole 40 mg daily, compared with 64.2{\%} on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60{\%} of patients after 4 weeks, as compared to 21{\%} of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.",
keywords = "Drug resistance, Histamine H2-receptor blockers, Omeprazole, Ranitidine, Reflux esophagitis",
author = "Porro, {Gabriele Bianchi} and Fabio Pace and Alberto Peracchia and Luigi Bonavina and Sergio Vigneri and Anna Scialabba and Massimo Franceschi",
year = "1992",
language = "English",
volume = "15",
pages = "192--198",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine

AU - Porro, Gabriele Bianchi

AU - Pace, Fabio

AU - Peracchia, Alberto

AU - Bonavina, Luigi

AU - Vigneri, Sergio

AU - Scialabba, Anna

AU - Franceschi, Massimo

PY - 1992

Y1 - 1992

N2 - Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.

AB - Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.

KW - Drug resistance

KW - Histamine H2-receptor blockers

KW - Omeprazole

KW - Ranitidine

KW - Reflux esophagitis

UR - http://www.scopus.com/inward/record.url?scp=0026656870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026656870&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 192

EP - 198

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 3

ER -